Dr Tom C Deroche, MD in Clackamas, OR - Medicare Pathology

Dr Tom C Deroche, MD is a medicare enrolled "Pathology - Anatomic Pathology & Clinical Pathology" physician in Clackamas, Oregon. He went to Saint Louis University School Of Medicine and graduated in 2005 and has 19 years of diverse experience with area of expertise as Pathology. He is a member of the group practice Kaiser Foundation Health Plan Of The Northwest and his current practice location is 10180 Se Sunnyside Rd, Clackamas, Oregon. You can reach out to his office (for appointments etc.) via phone at (503) 652-2880.

Dr Tom C Deroche is licensed to practice in Oregon (license number MD172846) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1407021512.

Contact Information

	Dr Tom C Deroche, MD
	10180 Se Sunnyside Rd, Clackamas, OR 97015-8970
	(503) 652-2880
	Not Available

Physician's Profile

Full Name	Dr Tom C Deroche
Gender	Male
Speciality	Pathology
Experience	19 Years
Location	10180 Se Sunnyside Rd, Clackamas, Oregon
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Tom C Deroche attended and graduated from Saint Louis University School Of Medicine in 2005

NPI Data:

NPI Number: 1407021512
Provider Enumeration Date: 04/29/2008
Last Update Date: 05/17/2022

Medicare PECOS Information:

PECOS PAC ID: 7719160415
Enrollment ID: I20150921001264

Medical Identifiers

Medical identifiers for Dr Tom C Deroche such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1407021512	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ZP0102X	Pathology - Anatomic Pathology & Clinical Pathology	MD172846 (Oregon)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Kaiser Foundation Health Plan Of The Northwest	5799688230	1482

News Archive

Employer health care costs projected to rise by nearly 10% in 2008 and 2009

Employer health care costs are expected to increase by 9.9% in 2008 - more than double annual inflation rates - and 9.6% in 2009, according to a study released Tuesday by PricewaterhouseCoopers, the AP/Minneapolis Star Tribune reports.

ImmunoLin provides immediate benefit to the function of immune system and gut

A new study provides evidence that ImmunoLin®, an all natural and GRAS approved source of immunoglobulin, will provide immediate benefit to the function of the immune system and the gut. Immunoglobulins, or antibodies, are specialized proteins found in blood that the immune system naturally produces for immunity.

Discovery offers novel possibilities to target drug-resistant HER2-positive cancers

SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells.

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert Fenstermaker, MD, and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical Co. Ltd. based in Shanghai, China.

Ashoka and Boehringer Ingelheim initiative to promote health

The social entrepreneurial organization Ashoka and pharmaceutical company Boehringer Ingelheim on Tuesday announced they are launching a three-year global initiative aimed at "promoting healthy individuals, families and communities by identifying and supporting the most promising solutions to challenging health problems," according to an Ashoka press release.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Tom C Deroche allows following entities to bill medicare on his behalf.

Entity Name	Kaiser Foundation Health Plan Of The Northwest
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799

News Archive

Employer health care costs projected to rise by nearly 10% in 2008 and 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

Discovery offers novel possibilities to target drug-resistant HER2-positive cancers

SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells.

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

Ashoka and Boehringer Ingelheim initiative to promote health

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Tom C Deroche is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Tom C Deroche, MD 13705 Ne Airport Way Ste C, Portland, OR 97230-1048 Ph: (503) 652-2880	Dr Tom C Deroche, MD 10180 Se Sunnyside Rd, Clackamas, OR 97015-8970 Ph: (503) 652-2880

News Archive

Employer health care costs projected to rise by nearly 10% in 2008 and 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

Discovery offers novel possibilities to target drug-resistant HER2-positive cancers

SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells.

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

Ashoka and Boehringer Ingelheim initiative to promote health

Pathology Doctors in Clackamas, OR

Dr. Karen Gunson, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 13309 Se 84th Ave Ste 100, Clackamas, OR 97015 Phone: 971-673-8216 Fax: 971-673-8321
Dr. Larry Victor Lewman, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 13309 Se 84th Ave Ste 100, Clackamas, OR 97015 Phone: 971-673-8218 Fax: 971-673-8321
Dr. Christopher Ray Young, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 13309 Se 84th Ave Ste 100, Clackamas, OR 97015 Phone: 971-673-8220 Fax: 971-673-8321
Dr. Clifford Conrad Nelson, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 13309 Se 84th Ave, Suite 100, Clackamas, OR 97015 Phone: 971-673-8200
Dr. Daniel Wade Davis, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 13309 Se 84th Ave Ste 100, Clackamas, OR 97015 Phone: 971-673-8200

Dr Tom C Deroche, MD - Medicare Pathology in Clackamas, OR

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Employer health care costs projected to rise by nearly 10% in 2008 and 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

Discovery offers novel possibilities to target drug-resistant HER2-positive cancers

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

Ashoka and Boehringer Ingelheim initiative to promote health

Medicare Reassignments

Employer health care costs projected to rise by nearly 10% in 2008 and 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

Discovery offers novel possibilities to target drug-resistant HER2-positive cancers

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

Ashoka and Boehringer Ingelheim initiative to promote health

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Employer health care costs projected to rise by nearly 10% in 2008 and 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

Discovery offers novel possibilities to target drug-resistant HER2-positive cancers

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

Ashoka and Boehringer Ingelheim initiative to promote health

Pathology Doctors in Clackamas, OR